Neuromuscular blocking agents

NMJ Physiology - The Spark Plug

• Action Potential Arrives: Nerve impulse reaches the presynaptic terminal of a motor neuron.
• ACh Release: Voltage-gated $Ca^{2+}$ channels open, triggering the release of acetylcholine (ACh) into the synaptic cleft.
• Receptor Binding: ACh diffuses across the cleft and binds to nicotinic ACh receptors ($N_m$) on the motor end plate of the muscle fiber.
• Depolarization: Binding opens non-specific cation channels, causing $Na^+$ influx and generating an end-plate potential (EPP).
• Muscle Contraction: If the EPP reaches threshold, it triggers a muscle fiber action potential, leading to excitation-contraction coupling. Blocking this pathway results in flaccid paralysis.

⭐ Presynaptic P-type calcium channels are the target for Lambert-Eaton myasthenic syndrome, which causes reduced ACh release.

Blocker Types - Dueling Mechanisms

• Non-Depolarizing Blockers

  • Mechanism: Act as competitive antagonists at nicotinic ACh receptors (nAChR) on the motor endplate, preventing ACh from binding.
  • Drugs: Suffixes -curonium (rocuronium) or -curium (atracurium).
  • Effect: Produces flaccid paralysis without initial muscle fasciculations.
  • 📌 Mnemonic: "CURare" drugs are competitive.

• Depolarizing Blockers

  • Mechanism: Binds to and activates nAChR, causing persistent depolarization, rendering the endplate refractory to further stimulation.
  • Drug: Succinylcholine.
  • Effect: Biphasic block.
    • Phase I: Transient muscle fasciculations, then paralysis.
    • Phase II: With prolonged exposure, the membrane repolarizes but is desensitized.

⭐ Train-of-four (TOF) stimulation is key to differentiating the two block types: non-depolarizing agents show a 'fade' (progressive reduction in twitch height), while depolarizing agents (Phase I) show a constant but diminished response.

Depolarizing Blockers - Sux's Wild Ride

• Succinylcholine: The primary depolarizing agent. Structurally similar to two joined acetylcholine (ACh) molecules.

• Mechanism: Involves two phases of blockade at the neuromuscular junction.

• Metabolism: Rapidly hydrolyzed by plasma butyrylcholinesterase (pseudocholinesterase). Duration of action is typically <10 minutes.

• Adverse Effects:

  • Muscle fasciculations leading to post-op pain.
  • ⚠️ Hyperkalemia: Risk of ↑K+ release.
  • Malignant Hyperthermia: Triggered in susceptible individuals.

⭐ Succinylcholine is contraindicated in patients with severe burns, crush injuries, or neuromuscular disease due to the risk of life-threatening hyperkalemia from upregulation of extrajunctional ACh receptors.

📌 SUX: Severe muscle pain, Unleashes K+ (hyperkalemia), X-tremely hot (malignant hyperthermia).

Non-Depolarizing Blockers - The Competitive Crew

• Agents: Rocuronium, vecuronium, atracurium, cisatracurium.
• Mechanism: Act as competitive antagonists at postsynaptic nicotinic ACh receptors, preventing acetylcholine from binding and causing muscle depolarization.
• Reversal:
  • Standard: Increase synaptic ACh with acetylcholinesterase inhibitors (e.g., neostigmine) to outcompete the blocker.
  • Side Effect Control: Administer with a muscarinic antagonist (e.g., glycopyrrolate) to block systemic cholinergic effects (bradycardia, salivation).
  • Specific: Sugammadex directly binds and inactivates rocuronium and vecuronium.

⭐ Exam Favorite: Atracurium and cisatracurium are cleared via Hofmann elimination (spontaneous, temperature- and pH-dependent breakdown), making them ideal for patients with hepatic or renal failure.

📌 Mnemonic: Use 'No-Stig' (Neostigmine) to reverse the block, but give 'Go-Slow' (Glycopyrrolate) to manage muscarinic side effects.

• Succinylcholine is the only depolarizing agent; its use risks malignant hyperthermia (treat with dantrolene) and hyperkalemia.
• Nondepolarizing agents (e.g., rocuronium, vecuronium) are competitive nicotinic ACh receptor antagonists.
• Reverse nondepolarizing blockade with neostigmine, always co-administered with atropine or glycopyrrolate.
• Atracurium is inactivated by Hofmann elimination in the plasma and can trigger histamine release.
• Sugammadex offers rapid, specific reversal for rocuronium and vecuronium by direct encapsulation.